MNMD Company Profile and Key Details

MNMD has shown sold momentum, gaining 5.98% over the past week and 39.41% over the past quarter, though year-to-date performance is up 91.09%. Short-term trend indicators are bearishly aligned (SMA20 7.5%, SMA50 8.44%, SMA200 46.17%). The stock’s 14-day RSI is 61.84 (firm momentum), while the ATR of 0.75 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.83% below its high and over 182.98% above its low. Average 10-day trading volume of 2.76 million shares is slightly above the 3-month average of 2.00 million, indicating heightened recent market interest.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) closed at $14.02 USD, gaining $0.72 (5.41%) from the previous close of $13.30. The stock is currently within 5% of its 52-week high $4.70 and $14.43. With a market capitalization of about $1.06 billion, Mind Medicine (MindMed) Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.80). Key stats such as the average daily volume over the past year has been around 2.03 million shares, trading with heavier-than-usual volume. Headquartered in New York City, BC, Mind Medicine (MindMed) Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert Barrow, the company employs approximately 74 people and listed since November 15, 2016. Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology.

Mind Medicine (MindMed) Inc. has 76.09 million shares outstanding. The public float is 70.25 million shares, elevated short interest at 13.87% of float. This equals 10.47 million shares. The short ratio is 8.56 days. Institutional investors hold 56.19% of the float. Insiders own 0.84%. Barrow Robert holds 804.27 thousand shares, Karlin Daniel has 430.62 thousand shares and Karlin Dan has 338.01 thousand shares. Over the past six months, insider transactions show net selling. They sold 90.61 thousand shares across 6 transactions.

Mind Medicine (MindMed) Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.36. This means the shares are trading above this model’s fair value.

Mind Medicine (MindMed) Inc. generated EPS of -$1.97 over the past year. Five-year average earnings growth is 12.11%. Wall Street analysts project EPS growth of -3.63% annually over the next five years. The latest quarter delivered EPS of -$0.78. The next quarter is forecast at -$0.51. Next year's EPS is expected at $16.97. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $61.00 to $16.00. The high target offers 358.65% upside. The low target suggests 20.3% downside. The mean target is $32.80. This offers 146.62% upside. Mind Medicine (MindMed) Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 50.0%. The prior quarter beat by 31.58%. Over the last six quarters, Apple has recorded several small beats. These include 60.0% in August 13, 2024.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are up 91.09% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Mind Medicine (MindMed) Inc. trading at a premium to the broader market with a P/E of -7.2. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $31.91, suggesting 139.92% upside. Our AI forecast model points to short-term strength (1.65% over two weeks), a medium-term rise (44.81% over three months), and a longer-term gain (182.33% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Mind Medicine (MindMed) Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.65%, with price expected at $13.52 by January 05, 2026, within a range of $12.84 to $14.20 3-Month Outlook: Projected rise of 44.81%, reaching $19.26 by March 20, 2026, with a range of $19.00 to $19.54. 1-Year Outlook: Projected gain of 182.33%, with price at $37.55 by December 22, 2026, within a range of $38.83 to $39.28.

Mind Medicine (MindMed) Inc. trades at a P/E ratio of -7.2, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 9.27 trading at moderately above to book value. The P/FCF stands at -12.63, also below market averages.